Vascular endothelial function and blood pressure homeostasis in mice overexpressing IGF binding protein-1

Diabetes

Volumn 52, Issue 8, 2003, Pages 2075-2082

  Wheatcroft, Stephen B ^a   Kearney, Mark T ^a,c   Shah, Ajay M ^a   Grieve, David J ^a   Williams, Ian L ^a   Miell, John P ^a,b   Crossey, Paul A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; GENE OVEREXPRESSION; HEMODYNAMICS; HYPERINSULINEMIA; INSULIN SENSITIVITY; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; VASOMOTOR REFLEX;

ANIMALS; AORTA; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HOMEOSTASIS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; MALE; MICE; MICE, INBRED CBA; MICE, TRANSGENIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RISK FACTORS; VASOCONSTRICTION;

EID: 0041765677     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.8.2075     Document Type: Article

References (50)

1. Wever R, Luscher T, Consentino F, Rabelink TJ: Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 97:108-112, 1998
2. Harrison DG: Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100:2153-2157, 1997
3. Grundy SM: Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 105:2696-2698, 2002
4. Wheatcroft SB, Williams IL, Shah AM, Kearney MT: Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 20:255-268, 2003
5. Lewitt MS, Baxter RC: Insulin-like growth factor-binding protein-1: a role in glucose counterregulation? Mol Cell Endocrinol 79:C147-C152, 1991
6. Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest 98:894-898, 1996
7. Cefalu WT: Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 226:13-26, 2001
8. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
9. Pyorala M, Miettinen H, Laakso M, Pyorala K: Hyperinsulmemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 98:398-404, 1998
10. Baxter RC: Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 42:140-144, 1994
11. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG: Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28:619-637, 1996
12. Lee PD, Giudice LC, Conover CA, Powell DR: Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 216:319-357, 1997
13. Lee PD, Conover CA, Powell DR: Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med 204:4-29, 1993
14. Ketelslegers JM, Maiter D, Maes M, Underwood LE, Thissen JP: Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Horm Res 45:252-257, 1996
15. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K: Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 79:872-878, 1994
16. Mohamed-Ali V, Pinkney JH, Panahloo A, Cwyfan-Hughes S, Holly JM, Yudkin JS: Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome. Clin Endocrinol (Oxf) 50:221-228, 1999
17. Harrela M, Koistinen R, Tuomilehto J, Nissinen A, Seppala M: Low serum insulin-like growth factor-binding protein-1 is associated with an unfavourable cardiovascular risk profile in elderly men. Ann Med 32:424-428, 2000
18. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A, Gibson JM: Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 44:333-339, 2001
19. Gibson JM, Westwood M, Young RJ, White A: Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 81:860-863, 1996
20. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW: Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 18:277-282, 1998
21. Heald AH, Siddals KW, Fraser W, Taylor W, Kaushal K, Morris J, Young RJ, White A, Gibson JM: Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 51:2629-2636, 2002
22. Leinonen ES, Salonen JT, Salonen RM, Koistinen RA, Leinonen PJ, Sarna SS, Taskinen MR: Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 25:1807-1812, 2002
23. Crossey PA, Jones JS, Miell JP: Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes 49:457-465, 2000
24. D'Ercole AJ, Dai Z, Xing Y, Boney C, Wilkie MB, Lauder JM, Han VK, Clemmons DR: Brain growth retardation due to the expression of human insulin like growth factor binding protein-1 in transgenic mice: an in vivo model for the analysis of IGF function in the brain. Brain Res Dev Brain Res 82:213-222, 1994
25. Rajkumar K, Barron D, Lewitt MS, Murphy LJ: Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 136:4029-4034, 1995
26. Gay E, Seurin D, Babajko S, Doublier S, Cazillis M, Binoux M: Liver-specific expression of human insulin-like growth factor binding protein-1 in transgenic mice: repercussions on reproduction, ante- and perinatal mortality and postnatal growth. Endocrinology 138:2937-2947, 1997
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
28. Crossey PA, Pillai CC, Miell JP: Altered placental development and intrauterine growth restriction in IGF binding protein-1 transgenic mice. J Clin Invest 110:411-418, 2002
29. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 106:453-458, 2000
30. Hellenius ML, Brismar KE, Berglund BH, de Faire UH: Effects on glucose tolerance, insulin secretion, insulin-like growth factor 1 and its binding protein, IGFBP-1, in a randomized controlled diet and exercise study in healthy, middle-aged men. J Intern Med 238:121-130, 1995
31. Mortensen DL, Won WB, Siu J, Reifsnyder D, Gironella M, Etcheverry T, Clark RG: Insulin-like growth factor binding protein-1 induces insulin release in the rat. Endocrinology 138:2073-2080, 1997
32. Chen YL, Messina EJ: Dilation of isolated skeletal muscle arterioles by insulin is endothelium dependent and nitric oxide mediated. Am J Physiol 270:H2120-H2124, 1996
33. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 97:2601-2610, 1996
34. Laight DW, Kaw AV, Carrier MJ, Anggard EE: Pharmacological modulation of endothelial function by insulin in the rat aorta. J Pharm Pharmacol 50:1117-1120, 1998
35. Baron AD: Hemodynamic actions of insulin. Am J Physiol 267:E 187-E202, 1994
36. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B, Scherrer U: Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104:342-345, 2001
37. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87:2246-2252, 1991
38. Kearney MT, Cowley AJ, Stubbs TA, Evans A, Macdonald IA: Depressor action of insulin on skeletal muscle vasculature: a novel mechanism for postprandial hypotension in the elderly. J Am Coll Cardiol 31:209-216, 1998
39. Kearney MT, Cowley AJ, Stubbs TA, Macdonald IA: Effect of a physiological insulin infusion on the cardiovascular responses to a high fat meal: evidence supporting a role for insulin in modulating postprandial cardiovascular homoeostasis in man. Clin Sci (Colch) 91:415-423, 1996
40. Masuo K, Mikami H, Ogihara T, Tuck ML: Mechanisms mediating postprandial blood pressure reduction in young and elderly subjects. Am J Hypertens 9:536-544, 1996
41. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101:676-681, 2000
42. Ding YVN, Coulson R, Kananna VS, Roh DD: Effects of simulated hyperglycaemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab 279:E11-E17, 2000
43. Kobayashi T, Kamata K: Effect of chronic insulin treatment on NO production and endothelium-dependent relaxation in aortae from established STZ-induced diabetic rats. Atherosclerosis 155:313-320, 2001
44. - imbalance in insulin-resistant rat aorta. Diabetes 48:2437-2445, 1999
45. Firth SM, Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854, 2002
46. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR: Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 90:10553-10557, 1993
47. Kullo IJ, Mozes G, Schwartz RS, Gloviczki P, Tsutsui M, Katusic ZS, O'Brien T: Enhanced endothelium-dependent relaxations after gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries. Hypertension 30:314-320, 1997
48. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, Sakoda T, Kurihara H, Yazaki Y, Yokoyama M: Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 102:2061-2071, 1998
49. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, Bonadonna RC: Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105:576-582, 2002
50. Abe H, Yamada N, Kamata K, Kuwaki T, Shimada M, Osuga J, Shionoiri F, Yahagi N, Kadowaki T, Tamemoto H, Ishibashi S, Yazaki Y, Makuuchi M: Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 101:1784-1788, 1998